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Background: A pre-erythrocytic vaccine could provide a useful tool for burden reduction and eventual eradication
of malaria. Mathematical malaria models provide a mechanism for evaluating the effective burden reduction across
a range of transmission conditions where such a vaccine might be deployed.
Methods: The EMOD model is an individual-based model of malaria transmission dynamics, including vector
lifecycles and species-specific behaviour, coupled to a mechanistic intrahost model of malaria parasite and host
immune system dynamics. The present work describes the extension of the EMOD model to include diagnoses of
severe malaria and iterative calibration of the immune system parameters and parasite antigenic variation to
age-stratified prevalence, incidence and severe disease incidence data obtained from multiple regions with broadly
varying transmission conditions in Africa. An ensemble of calibrated model parameter sets is then employed to
evaluate the potential impact of routine immunization with a pre-erythrocytic vaccine.
Results: The reduction in severe malaria burden exhibits a broad peak at moderate transmission conditions. Under
sufficiently intense transmission, a vaccine that reduces but does not eliminate the probability of acquisition from a
single challenge bite may delay infections but produces minimal or no net reduction. Conversely, under sufficiently
weak transmission conditions, a vaccine can provide a high fractional reduction but avert a relatively low absolute
number of cases due to low baseline burden.
Conclusions: Roll-out of routine immunization with pre-erythrocytic malaria vaccines can provide substantial
burden reduction across a range of transmission conditions typical to many regions in Africa.
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Recent years have seen encouraging progress in the re-
duction of global malaria burden, with the WHO’s global
mortality estimates declining roughly 30% from 2000 to
2013 [1]. However, malaria continues to kill hundreds of
thousands a year, with the burden of mortality falling
most heavily on children in sub-Saharan Africa. Improve-
ments in vector control, diagnostics and treatment have
all contributed to the declining mortality [2-4], and a pre-
ventative vaccine could provide an important additional
tool to the malaria control and eradication effort. Math-
ematical models of malaria transmission and within-host
disease progression can aid in understanding the effects of* Correspondence: kmccarthy@intven.com
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unless otherwise stated.potential vaccine distributions under a broad range of
transmission conditions. A variety of potential vaccines
are under investigation; depending on which stage of the
parasite lifecycle is targeted, a vaccine could act to prevent
human acquisition, reduce morbidity post-acquisition,
or prevent transmission from human hosts back to the
mosquito vectors.
The EMOD model is an individual-based, stochastic
simulation framework that couples a mechanistic model
of intra-host parasite lifecycle and immune system re-
sponse dynamics to a detailed model of the mosquito
population lifecycle, including responses to changes in cli-
mate and descriptions of species-dependent behaviours
[5-9]. Campaign interventions targeting the vector popula-
tion (insecticide-treated nets, habitat clearance) or theral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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etc.) can be flexibly distributed to specified subpopula-
tions, e.g., age-based immunization schedules, calendar-
based distribution campaigns or treatment-seeking upon
onset of symptoms.
Malaria control efforts rely on multiple tools to re-
duce disease burden: vector control techniques, chemo-
prophylaxis, and post-exposure drug treatment [10].
The proliferation of drug-resistant parasites [11] or
insecticide-resistant mosquitos [12] remains a concern
for these techniques, and malaria vaccines could pro-
vide a crucial tool in burden reduction and potential
elimination of malaria. Pre-erythrocytic vaccines target
the Plasmodium falciparum parasite prior to blood-
stage disease, aiming to block liver-stage infection from
occurring or from progressing to blood-stage infection,
thus preventing the onset of symptomatic malaria as
well as onward transmission of gametocytes. Among
current pre-erythrocytic vaccine candidates, the RTS,S
vaccine is in the most advanced stage of clinical trials
[13-15]. Human trials of the vaccine (with various adju-
vants) have been conducted since the early 1990s, demon-
strating safety and immunogenicity in clinical and field
settings [16]. A recent Phase 3 trial across eleven African
sites [13] reports promising results; a 3-dose infant
immunization schedule provides efficacies against clinical
malaria of 46% over an 18 month follow-up period, with
similarly strong efficacies against severe malaria and mal-
aria hospitalization (34% and 41%, respectively).
An effective pre-erythrocytic vaccine could provide a
useful tool for burden reduction and eventual eradica-
tion of malaria. However, a vaccine that provides limited
protection against infection could delay the development
of adaptive immunity to blood-stage disease, increasing
the malaria burden in older children whose vaccine-
derived immunity has waned. This “rebound effect” has
been observed to occur in field studies of intermittent
preventive treatment and chemoprophylaxis [17,18], and
should be investigated in the case of pre-erythrocytic
vaccines. Evaluation of the effective burden reduction
across the broad range of transmission conditions where
such a vaccine could be deployed is a natural target for
mathematical malaria models [19,20].
Methods
The EMOD malaria model has been described in detail
in previous papers [5-9]. The intrahost model features a
mechanistic description of within-host infection dynam-
ics that lead to the acquisition of parasitological and
clinical immunities with repeated exposure. This model
includes descriptions of both the innate and adaptive
human immune responses to antigens presented by mer-
ozoite surface proteins (MSP), unique epitopes of P. fal-
ciparum erythrocyte membrane proteins (PfEMP), andcross-reactive PfEMP epitopes. Each of these antigenic
compartments is also allowed a configurable number of
antigenic variants [8,21-23]. The adaptive immune sys-
tem response to each variant within each antigenic com-
partment is described by a growth rate, capacity, decay
rate, memory level, and parasite clearance efficacy. The
unique PfEMP epitopes are also characterized by a
switching rate, allowing the presentation of distinct vari-
ants over the course of a single infection. Individual
body temperatures and red blood cell (RBC) concentrations
are tracked throughout the simulation to identify clinical
and severe disease incidence (defined in Calibration subsec-
tion). Body temperature is governed by innate cytokine pro-
duction, which is stimulated by parasite density (through a
pyrogenic threshold) and schizont rupture events, and miti-
gated by the production of adaptive antibodies [6]. RBC
concentrations are governed by processes of destruction
through schizont rupture and production by the host.
Calibration
Prior to evaluating the efficacy of a pre-erythrocytic vac-
cine in field conditions, the model was calibrated in two
steps. First, age-stratified prevalence and fever incidence
curves were used to calibrate parameters governing anti-
genic dynamics and immune response, and then age-
stratified severe disease incidence curves were used to
calibrate model parameters governing the probabilistic
presentation of a severe malarial incident.
The parameters of the immune system model that are
most relevant to acquisition of long-term clinical and
parasitological immunity were calibrated to age-stratified
prevalence and incidence data from six sites experien-
cing measured entomological inoculation rates (EIRs)
ranging from 18 to over 300. Prevalence data comes
from Matsari, Sugungum and Rafin Marke in Nigeria
[24], and Namawala, Tanzania [25]; incidence data was
obtained from Ndiop and Dielmo, Senegal [26-28].
Clinical incidence data present some challenges for
model calibration. In a model of malaria transmission with
no other pathogens, as is the case here, all fevers are
caused by malaria. This is not the case in field studies, and
the attribution of clinical symptoms can be problematic,
particularly at high prevalence. Studies often use cutoffs
on the parasitaemia level concurrent with fever incidence
to determine a ‘malaria attributable fraction’, but this is
subject to heterogeneities based on local transmission in-
tensity [29]. Other works have also noted that higher fre-
quencies of active case detection visits tend to produce
higher estimates of incidence [30,31]. It is not obvious
whether this correlation arises because of over-attribution
of non-malarial fevers caught in frequent visits, or to true
malaria-attributable fevers being missed in between visits.
At these Senegal sites, patients were visited three times
per week, and the present work makes no attempt to
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model-predicted fevers from being attributed to malaria if
concurrent parasitaemia is low. Such corrections may be-
come necessary when expanding the set of calibration sites
or comparing predicted incidence rates against out-of-
sample data.
At the Senegal study sites, patients were also treated
with quinine when fever presented with concurrent
parasitaemia. The high rate of case detection combined
with rapid treatment could exert strong effects on the
development of immunity. To account for this, the sim-
ulated population undergoes a burn-in of forty years,
during which the population is exposed to the expected
transmission conditions but does not undergo rapid case
detection and treatment; this setup prevents high treat-
ment rates from limiting age-dependent immunity devel-
opment in the population. After the burn-in period, fever
incidence reporting begins, and individuals who present
fever begin parasite-clearing treatment with a 30% prob-
ability per day from the fever onset, meant to roughly cap-
ture the ‘time to next visit’ for fever detection. The rapid
parasite clearance after fever onset also likely prevents the
dataset from informing the model calibration with respect
to the effects of coinfection on morbidity.
The simulated transmission conditions at each site are
characterized by a total EIR and a normalized seasonal
profile. Simulations with local climate data were neces-
sary to determine the seasonal profile of certain sites,
while others were taken from literature. Throughout this
study, the annual EIR characterizes the biting rate expe-
rienced by grown adults; children experience a reduction
in this biting rate described by a piecewise-linear func-
tion that approximates their expected surface area as a
function of age (i.e., biting rates are assumed to be pro-
portional to skin surface area). Age-dependent biting is
well documented [32,33] and has been used in previous
modelling work [34].
Because of the interactions between the human and
vector systems in the EMOD model, broad variations in
human immune dynamics induce variations in the trans-
mission conditions. This presents a difficulty in the
calibration process, as the target distributions are age-
specific prevalence and incidence curves determined at
measured EIRs. It is computationally expensive to adjust
vector habitats at each tested set of intrahost parameters
to compare results at equal transmission levels. To re-
move this complication, the measured transmission con-
ditions were reproduced by removing the vectors from
the simulation entirely, and instead subjecting the simu-
lated individuals to periodic sporozoite challenge at a
known intensity. The frequency of challenge is varied
monthly to reproduce seasonal variation in EIR.
The model parameters included in the calibration are
the number of antigenic variants in each of the threeimmune compartments, the killing strengths of the MSP
antigens and shared minor epitopes, and the PfEMP
antigenic switching rate; other parameters of the model
had been calibrated to reproduce individual time courses
of infection and distributions of infection durations and
were held fixed during this calibration.
For each set of model input parameters, a set of simula-
tions are run to characterize outputs under the measured
transmission conditions at each of the field sites from the
data, and the overall likelihood of an input parameter set
is the product of likelihoods over the six sites. Simulated
prevalence output is modelled as random binomial slide
positivity measurements, characterized by a number of
slides viewed and an individual’s current blood parasite
density. The definition of a clinical malarial incident is
configurable in the EMOD model; for this study, a clinical
incident begins when an individual’s body temperature is
raised by 1.5°C. Parasite density alone does not trigger a
clinical incident, though temperature and parasite density
are implicitly linked through the innate immune response.
The clinical incident continues until the fever remains
below 0.5°C for two weeks; this refractory period prevents
the multiple recrudescent fever events typical to malaria
from being recorded as multiple independent clinical
incidents.
Incremental mixture importance sampling [35,36] was
employed for parameter space exploration and calibra-
tion. Once the target posterior likelihood has been suffi-
ciently well-sampled, this stage of calibration is finished
by producing an acceptable region of parameter space,
defined by placing a threshold on the overall log-
likelihood (based on Wilks’ theorem) and forming the
convex hull of all parameter sets above this threshold.
This calibrated parameter volume is used as an accept-
ance region for resampling model parameter sets. More
details of the simulation setup, likelihood functions and
algorithm can be found in Additional file 1.
The results of the model calibration to age-stratified
measurements of parasite prevalence and clinical inci-
dence are presented in Figure 1. The two left columns
present the measured fraction of children testing positive
for parasites by slide microscopy at four sites with annual
EIRs ranging from 18–329. The data are presented as
black points with statistical error bars, and the blue-
shaded regions that enclose the results of all simulations
passing the total log-likelihood threshold (100/95/68%
quantiles are presented in progressively darker shading).
The right column similarly presents the rate of fever inci-
dence at two sites, with annual EIRs of 20 and 200.
Sites with increasing annual EIR exhibit a more rapid
rise in detectable parasitaemia levels at the youngest
ages and a higher overall peak prevalence, but all sites
exhibit a decrease in prevalence over the second decade
of life. Above 20 years of age, the observed prevalence
Figure 1 (Two left columns) Age-stratified prevalence data and simulation results from four regions in Nigeria and Tanzania.
(Right column) Age-stratified incidence data and simulation results from two regions in Senegal. In both panels, the blue-shaded regions
represent the 68/95/100% quantiles of simulations passing the likelihood threshold.
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range of transmission intensities. In the two Senegal
sites, an order of magnitude increase in EIR produces a
substantially higher peak rate of clinical incidence, an
earlier peak age (2–3 in Dielmo vs 5–10 in Ndiop), and
a lower incidence rate in adults (approximately 0.6/year
in Ndiop vs 0.2/year in Dielmo). The more intense trans-
mission in Dielmo confers sufficient immune protection
that the cumulative lifetime incidence is lower than in
Ndiop [26].
The effects of each of the calibration parameters on the
features described above are not simple to describe, as
there are strong interactions among the terms. Broadly, in-
creasing the number of antigenic variants in the three im-
mune compartments delays the onset of parasitological
and symptomatic immunity, while the antibody killing
strengths to MSP and cross-reactive PfEMP epitopes most
strongly affect the magnitude of the prevalence and inci-
dence in early ages. The antigenic switching rate also
strongly affects the onset of symptomatic immunity; when
the switching rate is too slow, immunity is acquired slowly
as the host is presented with few variants in any individual
infection. The antigenic switching rate has also been con-
strained by previous work on the duration of infection and
infectiousness in naïve individuals [8].
The calibration procedure continues by sampling par-
ameter values from the acceptable regions defined in the
first stage and varying a new set of parameters governing
severe disease, targeting data on age-specific severe dis-
ease rates at five sites in The Gambia and Kenya [37],
and proportional rates of cerebral or anemic malaria
from seventeen sites across Africa [38]. In the EMOD
model, an individual’s current state is mapped onto three
probabilities of diagnosis of severe malaria due to three
underlying causes. An individual’s current RBC countsets a probability of diagnosis due to anaemia and asso-
ciated presentations, their current body temperature acts
as a proxy for presentation of severe cerebral malaria,
and their current parasitaemia level acts as a catch-all
proxy for other complications (e.g., respiratory involve-
ment). Similar protections to those described above re-
garding clinical incidents are in place to prevent a single
severe presentation from being recorded as multiple
incidents.
The functions translating RBC counts, asexual parasite
densities and fever levels to probabilities of diagnosis are
sigmoid (logistic) functions characterized by a width and
a midpoint. The functional form is:





Where k represents the inverse width, and x0 is the
threshold, at which the probability is equal to 0.5. The
calibration includes the widths and midpoints associated
with severe cerebral malaria or severe parasitaemia, a
multiplier governing how many red blood cells are
destroyed when a schizont ruptures, and the level of ma-
ternal antibody protection (which varies from site to site
based on measured transmission conditions – see
“Details of calibration setup” in Additional file 1 for
more details). The width and threshold for severe an-
aemia is not included in the calibration, because this
diagnosis in the source data is based on a well-defined
threshold at haemoglobin density of 5 g/dl. The fre-
quency of anaemia is governed by the competing pro-
cesses of erythrocyte destruction by rupturing schizonts
and increased erythropoiesis in response to decreased
haemoglobin density. Because these two effects produce
opposing results on the rate of severe anaemia, the
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hand-calibrated to measured individual time courses in
naïve patients, and only the erythrocyte destruction fac-
tor is varied in this calibration.
The results of calibrating the model to age-stratified se-
vere disease diagnoses are presented in Figure 2. Age-
stratified total severe disease incidence rates, measured
from hospital records and census data, at five sites with
parasite prevalence rates in one to nine years olds ranging
from 2 to 83% (mapped through simulation to annual
EIRs ranging from 0.1 to 55) are presented on the left.
The proportions of severe disease incidence in the under
24 months and five to nine years age bins, and the propor-
tions of cerebral and anemic disease at 17 sites, along with
simulation results, are presented on the right. The blue-
shaded regions are defined as in Figure 1.
In the parameter region favored post-calibration, the
probability of experiencing a severe cerebral malaria epi-
sode is essentially zero for low-grade fevers and in-
creases rapidly over a range of body temperatures from
40-41°C (base body temperature is assumed to be 37°C).
Similarly, a severe disease episode caused by hyperpara-
sitaemia is highly unlikely at parasite densities below ap-
proximately 200,000 per μl, rapidly increasing to a
probability approaching 1 by approximately 400,000 per
μl (figures available in Additional file 1).
Sites with increasing transmission intensity exhibit an
earlier peak age in severe disease rate, and a correspond-
ing increase in the proportion of severe disease due to
anemia. Maternal antibodies play a large role in the ini-
tial rise in severe incidence. The degree of protection
conferred by maternal antibodies was modelled as an
increasing function of transmission intensity, but a
mother’s antibody levels against particular antigenic
variants were not considered in these simulations. The
cumulative severe disease incidence is highest atFigure 2 (Left) Age-stratified severe disease incidence data and result
y-axis when comparing. (Right) Proportions of severe disease incidence in va
68/95/100% quantiles of simulations passing the likelihood threshold. PfPR2–10 ismoderate EIRs. The model predicts that under intense
transmission conditions, many children are exposed to
the parasite while maternal antibodies still provide suffi-
cient protection to prevent severe symptoms, and these
early exposures confer a degree of protection against se-
vere malaria in future infections. This idea has also been
hypothesized to explain observations that cumulative
paediatric severe malaria incidence is highest under mod-
erate conditions and declines at extremely high levels of
transmission [37,39]. The other five calibration parameters
interact strongly in setting the overall rate of severe dis-
ease incidence as well as the proportions of severe disease
ascribed to the three underlying mechanisms.
The limitations of this calibration procedure are worth
addressing here. The prevalence and incidence calibra-
tion was performed only to sites experiencing annual
EIRs > 18, which represents substantially higher trans-
mission intensity than currently experienced by most of
the African population [40]. To provide confidence that
the calibrated model can reasonably be applied to study
lower transmission intensities, the results of this calibra-
tion procedure were checked against data outside of the
calibration sample down to annual EIRs of 1. Details and
figures are contained in Additional file 1. Individuals in
the model are also homogenous in terms of immune sys-
tem dynamics, response to treatment, and biting risk.
Individual- and site-level heterogeneities in these quan-
tities and others have been observed in studies [14,41-45]
and can exhibit significant effects on population-level data.
These effects are under consideration in extensions to the
present work.
Parameter ensemble model vaccine evaluation
After calibration, the effects of a potential rollout of a
pre-erythrocytic vaccine were evaluated across a wide
range of transmission conditions and for an ensemble ofs from simulations from five regions in Africa; note the changing
rious categories. In both panels, the blue-shaded regions represent the
the proportion of 2–10 years olds testing positive for falciparum parasites.
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semble represents an independent set of input parameters
sampled from the 12-dimensional calibrated parameter
space. One-hundred and seventy parameter sets were in-
cluded in the ensemble; this number resulted from avail-
able computation time, rather than any considerations
specific to the analysis. Each of the 170 models was run
under a variety of transmission conditions; these were not
explicitly based on particular locations, but on a set of four
seasonal profiles and 18 total annual EIR magnitudes from
1 to 300. The four seasonal profiles included two realistic
profiles based on Sugungum, Nigeria and Mocuba,
Mozambique; a non-seasonal profile (constant rate of bit-
ing year-round); and a highly seasonal profile in which all
biting takes place at a flat rate for six months and no bit-
ing occurs for the remaining six months. Eight stochastic
repetitions of each model/transmission scenario were per-
formed, beginning at different times of the year to ameli-
orate potential systematic transient effects. Finally, each
setup was run once without vaccine distribution to pro-
vide baseline incidence rates, and run twice more with dif-
ferent vaccine efficacy profiles. Simulation outputs are
binned into six-month time periods for analysis.
Each individual simulation tracks a cohort of 1,000 in-
dividuals from birth until ten years of age. Individuals
receive vaccination between six and nine months of age.
This cohort-tracking simulation setup necessarily con-
siders only individual-level protection, ignoring any
population-level effects of the vaccination. Crosschecks
of results from cohort-based and full-population models
indicate that vaccinating only newborns with a waning
vaccine produces minimal effects on population-level
transmission intensity. The pre-erythrocytic vaccine
model is characterized by two parameters: an initial de-
gree of protection against infection and a half-life of pro-
tection. The degree of protection is defined as theFigure 3 The two pre-erythrocytic vaccine models evaluated: 80% eff
three-year halflife.reduction in probability of successful infection in a sin-
gle challenge bite. Two vaccine profiles were evaluated
against baseline – one with an initial degree of protec-
tion of 80% and a half-life of nine months (referred to as
fast-waning), and another with an initial protection of
60% but a half-life of three years (slow-waning). Figure 3
illustrates the two vaccine profiles evaluated.
Results
Over essentially the entire range of simulated transmission
conditions, the model predicts that a pre-erythrocytic vac-
cine delivered early in life results in a reduction in the rate
of severe malarial incidence for some period of time,
followed by a rebound in case counts, when the delayed
onset of acquired immunity results in vaccinated children
exhibiting a higher rate of severe malaria incidence than
unvaccinated children. At all levels of transmission, the
median net number of severe cases averted is positive,
though it approaches zero at the highest simulated EIR.
Figure 4 presents a typical illustrative example of this re-
duction and rebound behaviour, comparing the median
difference in disease incidence in the baseline scenario vs
the fast-waning vaccine scenario at an annual EIR of 10.
The figure shows a strong reduction in disease incidence
over the first two years’ post vaccination (at six months of
age), with a rebound effect causing a slightly higher rate of
severe disease in the vaccinated group as compared to
baseline after two-and-half years of age. The relative mag-
nitudes and timescales of case reduction and rebound are
most strongly dependent on the magnitude of the EIR and
the vaccine profile, and less so on the model input param-
eters or the seasonality (though it should be noted that the
idea of optimizing the timing of vaccination with respect
to local seasonal transmission was not tested). This section
will thus focus on case reduction as a function of annual
EIR and vaccine profile.icacy with nine-month halflife and 60% efficacy with
Figure 4 Severe disease incidence per 1,000 children per year at annual EIR = 15. The median baseline incidence is in dark red, and
incidence with the fast-waning vaccine is shown in dark blue. The region of incidence reduction at young ages is highlighted in light blue.
The disease incidence rebounds at ~2.5 years of age, and the rebound is highlighted in light red.
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rebound against the annual EIR for both vaccine models.
Referring to Figure 4, the period of case reduction is de-
fined as the interpolated crossing of the incidence curves
in baseline and vaccine scenarios (marked in black). The
eight stochastic repetitions are averaged, and the median/
quantiles are computed over the four seasonal profiles and
170 model parameter sets at each annual EIR value. As
should be expected, the protective period decreases as the
annual EIR increases for both vaccine profiles, and the
slowly waning vaccine provides a substantially longer
period of case reduction under low transmission intensity.
At higher transmission intensities, there is little difference
in the period of case reduction between the two vaccine
models. Modelling the vaccine as inducing imperfect,
probabilistic protection against infection in a single bite
implies that vaccination provides minimal effective protec-
tion when exposed to highly frequent infectious biting.Figure 5 Period of severe (left) and clinical (right) case reduction prio
models. The lines follow the median output value from the ensemble of mThe fractional (top) and absolute (bottom) reduction
in the cumulative severe (left) and clinical (right) inci-
dence over the first ten years of life are presented against
annual EIR for both vaccine profiles in Figure 6. The
total severe incidence reduction from distribution of a
pre-erythrocytic vaccine exhibits a broad maximum over a
range of moderate EIR values from roughly 10 to 40.
Under mild transmission conditions, the rate of severe
malaria is sufficiently low that, although the vaccine is
highly efficacious in terms of relative case reduction, the
absolute number of cases averted is quite small. And
under intense transmission, transmission is sufficiently
strong that a vaccine that acts to randomly block a max-
imum of 60 or 80% of potential acquisitions will provide
only a slight delay in disease acquisition, with insignificant
net burden reduction. It should be noted that the uncer-
tainties in the effects of vaccination arise from varying the
input parameters within the acceptable region defined inr to rebound for the fast-waning and slow-waning vaccine
odel parameters, and shaded areas outline the 68% quantiles.
Figure 6 EIR-dependent reduction in relative (top) and total (bottom) incidence of severe (left) and clinical (right) malaria; incidence,
per 1,000 children over the first ten years of life, for both vaccine models. The lines follow the median output value from the ensemble of
model parameters, and shaded areas outline the 68% quantiles.
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individual- or site-level heterogeneity) are outside of the
scope of the present work.
The maximal reduction in cumulative clinical incidence
occurs at lower annual EIRs, with a peak around an EIR of
5. At EIRs from 30–100, the rebound effect can actually
outweigh the initial case reduction, such that recipients of
the vaccine experience slightly increased cumulative rates
of clinical incidence. Reductions in transmission intensity
have previously been observed to produce increased cumu-
lative clinical incidence, so it is not unexpected that delayed
acquisition of protective immunity due to vaccination and
increased biting risk at older ages would combine to pro-
duce a net increase in cumulative incidence. At the highest
EIRs tested, vaccination produces no significant change in
total clinical incidence, as the intensity of transmission
overwhelms the partially protective vaccination.
The Malaria Atlas Project [40] has produced estimates
of transmission conditions on a finely partitioned spatial
grid throughout sub-Saharan Africa. These estimates are
combined with the results of this parameter ensemble
evaluation to produce the visualizations in Figure 7. TheFigure 7 (left) Malaria Atlas Project estimates of transmission intensit
per 1,000 children vaccinated over a ten-year horizon, 100% infant immuni
slow-waning vaccine.left panel maps the estimated EIR values, and the center
and right panels represent, for the fast and slow-waning
vaccines, respectively, the expected number of cases averted
per 1,000 children over a ten-year horizon. The resulting
maps project where the rollout of a pre-erythrocytic vaccine
would produce optimal benefits. The magnitude of the total
cases averted assumes 100% vaccination coverage of new-
borns, and does not consider coordinated rollout of the
vaccine with other transmission-reducing interventions.
Conclusions
Routine immunization of infants has proven to be an in-
credibly effective tool for reducing the burden of numer-
ous infectious diseases, particularly so for diseases in
which protection is long-lasting and naïve individuals
dominate the transmission chain. The present work
finds that routine immunization with a vaccine provid-
ing imperfect protection against acquisition of malaria
would provide optimal burden reduction within a range
of EIRs from approximately 10–40, where there is suffi-
cient burden for a vaccine to produce large effects, but
the frequency of parasite inoculation is not so high as toy (EIR values interpolated from PfPR2–10). Expected cases averted
zation coverage with (center) fast-waning vaccine and (right)
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indicate that, due to malaria’s ability to re-infect human
hosts numerous times, infant immunization alone does
not strongly perturb population-level transmission dy-
namics, and efforts towards local elimination must in-
clude broader intervention strategies. This evaluation
was performed using an ensemble of model parametriza-
tions, and it is found that the results are robust within a
broad volume of model parameter space consistent with
existing population-level measurements.
Extensions to this work may consider the effects of rou-
tine boosters as the vaccine’s protective effects wane, mass
vaccinations at sufficient scales to affect malaria’s trans-
mission chain, or correlated distribution of other anti-
malarial interventions in regions where the vaccine is
deployed. The presented models also do not consider po-
tential differences in overall mortality resulting from shift-
ing a fraction of the severe disease burden onto older
children. The calibration framework developed also allows
for straightforward addition of new data targets, including
similar measurements taken in other regions or different
types of measurement (e.g., measured parasite densities),
and further work along this direction is also merited.
Additional file
Additional file 1: Supplemental material: provides further details of
calibration setup, results, and validation.
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